Education
About Us
Working with TipRanks
Follow Us
Maged Shenouda Insider Profile
11 Followers
Maged Shenouda, CFO at Relmada Therapeutics, holds 788.34K shares in Relmada Therapeutics (Ticker: RLMD), holds 62.50K shares in Entero Therapeutics (Ticker: ENTO). Most recently, Maged Shenouda Bought ― shares of Relmada Therapeutics on Nov 06, 2025 for an estimated value of $1.10M.
Profitable Transactions
3 out of 6 Profitable Transactions
Average Return
+77.00%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Maged Shenouda holds in companies
Most Profitable Insider Trade
The most profitable trade made by Maged Shenouda
Maged Shenouda's Trading History
Relmada Therapeutics
Nov 06, 2025
CFO
Informative Buy
1.10M
$3.30M
Entero Therapeutics
Jan 02, 2019
CFO, Director
Informative Buy
26.20K
$177.50K
List of latest transactions for each holding click on a transaction to see Maged Shenouda's performance on stock
You May Also Like
Maged Shenouda insider profile FAQ
What is the percentage of profitable transactions made by Maged Shenouda?
The percentage of profitable transactions made by Maged Shenouda is 50%.
What is the average return per transaction made by Maged Shenouda?
The average return per transaction made by Maged Shenouda is 77.00%.
What stocks does Maged Shenouda hold?
Maged Shenouda holds: RLMD, ENTO stocks.
What was Maged Shenouda’s latest transaction?
Maged Shenouda latest transaction was an Informative Buy of $1.10M.
What was Maged Shenouda's most profitable transaction?
Maged Shenouda’s most profitable transaction was an Informative Buy of RLMD stock on May 20, 2025. The return on the trade was 561.60%.
What is Maged Shenouda's role in Relmada Therapeutics?
Maged Shenouda's role in Relmada Therapeutics is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.